Prof. Zhang Baoting

 

Prof. Zhang Baoting

Position Assistant Director
Office Room 101-E, Li Wai Chun Building, Chung Chi College, The Chinese University of Hong Kong, Hong Kong
Tel. (852) 3943 4285
Fax. (852) 3942 0941
Email This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Resume (Education and Working Experience)

Education:

  1. 1997 B.Med., Henan University of Traditional Chinese Medicine, China (Chinese Medicine)
  2. 2000 M.Med., Chengdu University of Traditional Chinese Medicine, China (Internal Medicine in Chinese Medicine)
  3. 2003 M.D., Shanghai University of Traditional Chinese Medicine, China (Internal Medicine in Chinese Medicine)

Working Experience:

  1. 2003-2005 Physician-in-charge, Shanghai Clinical Centre of Cardiovascular & Cerebrovascular Diseases in Traditional Chinese Medicine, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China
  2. 2006-2008 Postdoctoral Research Fellow, Department of Rehabilitation Sciences, Hong Kong Polytechnic University, Hong Kong
  3. 2008-2009 Postdoctoral Research Fellow, Department of Physiology, University of Sydney, Australia
  4. 2009-2010 Research Associate, Department of Rehabilitation Sciences, Hong Kong Polytechnic University, Hong Kong
  5. 2011-2011 Research Associate, Department of Orthopaedics & Traumatology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong
  6. 2011-2017 Assistant Professor, School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong
  7. 2017-now Associate Professor, School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong
  8. 2018-now Assistant Director, School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong
  

Teaching (Courses)

  1. BCME3102 Internal Medicine I
  2. BCME3202 Internal Medicine II
  3. BCME3208 Hong Kong Medical System
  4. BCME4107 Ent and Ophthalmology
  5. BCME4200 Research Methodologies in Chinese Medicine
  6. BCME5405 Internal Medicine (Chinese Medicine) I
  7. BCME5505 Internal Medicine (Chinese Medicine) II
  8. BCME6125 Selected Ancient Readings on Chinese Medicine
  9. BCME6160 Current Research Methodologies in Chinese Medicine and Thesis
  10. BCME6506 Research Methodologies in Acupuncture
  11. BCME6507 Seminars on Chinese Medicine
  12. BCME6510 Research Project in Acupuncture and Essay Writing

Research Interest

Exploration of molecular mechanisms and drug discovery with Chinese medicines, natural products and genetic approaches for:

  1. Musculoskeletal diseases (Osteoporosis, Bone fracture, Osteonecrosis, Sarcopenia, Unloading-related skeletal muscle atrophy and Traumatic muscle injury)
  2. Cancer (Ovarian cancer, Breast cancer and Osteosarcoma ect.)
  3. Cardio-cerebral diseases (Traditional Chinese Medicine theory and experimental research in atherosclerotic diseases)
  4. Pulmonary disease (Pneumoconiosis)


Selected Publications

  1. Zhang ZK, Li J, Guan D, Liang C, Zhuo Z, Liu J, Lu A, Zhang G, Zhang BT*. A newly identified lncRNA MAR1 acts as a miR-487b sponge to promote skeletal muscle differentiation and regeneration. Journal of Cachexia, Sarcopenia and Muscle 9(3):613-626, 2018. (Impact factor: 9.697; Ranking: Q1, 8 of 155 in Medicine, General & Internal)
  2. Li F, Lu J, Liu J, Liang C, Wang M, Wang L, Li D, Yao H, Zhang Q, Wen J, Zhang ZK, Li J, Lv Q, He X, Guo B, Guan D, Yu Y, Dang L, Wu X, Li Y, Chen G, Jiang F, Sun S, Zhang BT*, Lu A, Zhang G. A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer. Nature Communications 2017; 8: 1390. (Impact factor: 12.124; Ranking: Q1, 3 of 64 in Multidisciplinary Sciences)
  3. Liang C, Wang L, Zhang ZK, Wang C, Li J, He B, Zhu H, Zhang BT*, Li F, Lu A, Zhang G. Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGF-A in osteosarcoma. Biomaterials 147:68-85, 2017. (Impact factor: 8.402; Ranking: Q1, 1 out of 33 in Materials Science, Biomaterials)
  4. Li J, Liang C, Zhang ZK, Pan X, Peng S, Lee WS, Lu A, Lin Z, Zhang G, Leung WN, Zhang BT*. TAK1 inhibition attenuates both inflammation and fibrosis in experimental pneumoconiosis. Cell Discovery 3:17023, 2017.
  5. Liu J, Liang C, Guo B, Wu X, Li D, Zhang Z, Zheng K, Dang L, He X, Lu C, Peng S, Pan X, Zhang BT*, Lu A, Zhang G. Increased PLEKHO1 within osteoblasts suppresses Smad-dependent BMP signaling to inhibit bone formation during aging. Aging Cell 16(2): 360-376, 2017 (Impact factor: 6.714; Ranking: Q1, 2 of 49 in Geriatrics & Gerontology)
  6. Zhang ZK, Li J, Liu J, Guo B, Leung A, Zhang G, Zhang BT*. Icaritin requires Phosphatidylinositol 3 kinase (PI3K)/Akt signaling to counteract skeletal muscle atrophy following mechanical unloading. Scientific Reports 6:20300, 2016. (Impact factor: 4.259; Ranking: Q1, 10 of 64 in Multidisciplinary Sciences)
  7. Zhang ZK, Li J, Yan DX, Leung WN, Zhang BT*. Icaritin Inhibits Collagen Degradation-Related Factors and Facilitates Collagen Accumulation in Atherosclerotic Lesions: A Potential Action for Plaque Stabilization. International Journal of Molecular Sciences 17(2): E169, 2016. (Impact factor: 3.226; Ranking: Q2, 54 of 166 in Chemistry, Multidisciplinary)
  8. Liang C, Guo B, Wu H, Shao N, Li D, Liu J, Dang L, Wang C, Li H, Li S, Lau WK, Cao Y, Yang Z, Lu C, He X, Au DWT, Pan X, Zhang BT, Lu C, Zhang H, Yue KM, Qian A, Shang P, Xu JK, Xiao L, Bian Z, Tan W, Liang Z, He F, Zhang L, Lu AP & Zhang G. Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy. Nature Medicine 21(3):288-94, 2015. (Impact factor: 29.886 ; Ranking: Q1, 2 of 290 in Biochemistry & Molecular Biology; 3 of 190 in Cell Biology; 1 of 128 in Medicine, Research & Experimental)
  9. Peng S, Zhang G, Zhang BT*, Guo B, He Y, Bakker AJ, Pan X, Zhen W, Hung L, Qin L, Leung WN. The beneficial effect of Icaritin on osteoporotic bone is dependent on the treatment initiation timing in adult ovariectomized rats. Bone 55(1):230-40, 2013. (Impact factor: 4.140; Ranking: Q1, 32 of 138 in Endocrinology & Metabolism)
  10. Zhang G, Guo B, Wu H, Tang T, Zhang BT*, Zheng L, He Y, Yang Z, Pan X, Chow H, To K, Li Y, Li D, Wang X, Wang Y, Lee K, Hou Z, Dong N, Li G, Leung K, Hung L, He F, Zhang L*, Qin L*. A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. Nature Medicine 18(2): 307-314, 2012. (# Co-first author) (Impact factor: 29.886 ; Ranking: Q1, 2 of 290 in Biochemistry & Molecular Biology; 3 of 190 in Cell Biology; 1 of 128 in Medicine, Research & Experimental)

 *Corresponding author

Copyright © 2018 School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong. All Rights Reserved.